Evidence map›Paper›PMID 36786890›Full record

ReviewMedical oncology (Northwood, London, England)2023

The past, present, and future of immunotherapy for colorectal cancer.

Cole R Formslag, Lei Zhao, Aidan J Heslin, Cade C Lewis, Caleb W Miller, Qian Bai, Mark R Wakefield, Yujiang Fang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cole R Formslag *Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA, 50312, USA.
Lei Zhao *Department of Respiratory Medicine, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, AH, 230011, China.
Aidan J HeslinDepartment of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
Cade C LewisDepartment of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
Caleb W MillerDepartment of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
Qian BaiDepartment of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
Mark R WakefieldDepartment of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
Yujiang FangDepartment of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA, 50312, USA. yujiang.fang@dmu.edu.ORCID http://orcid.org/0000-0002-9107-7374

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is prevalent worldwide, with various factors influencing the survival rate of late-stage metastatic cases. Current standard treatments include surgical removal, adjuvant chemotherapy, and neoadjuvant chemotherapy. Novel immunotherapy research shows promising results for various cancer types, including colorectal cancer. Current immunotherapy options are limited to specific molecular subtypes of colorectal cancer, while the remaining are limited to standard protocol. This review article summarizes approved, developing, and potential sources for novel colorectal cancer immunotherapy treatment through active-specific, checkpoint inhibitor, cytokine, cytotoxic, and adoptive T-cell immunotherapy. Such a study would be beneficial to patients with colorectal cancer.

Indexed as

Colorectal NeoplasmsImmunotherapyChemotherapy, AdjuvantCytokinesHumansImmunotherapy, AdoptiveCytokinesCheckpoint inhibitorColorectal cancerCytokineImmunotherapy

Identifiers

PMID36786890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.